<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152931">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01772290</url>
  </required_header>
  <id_info>
    <org_study_id>GP28465</org_study_id>
    <nct_id>NCT01772290</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib</brief_title>
  <official_title>A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, open-label, 4-arm, multiple-dose study will  evaluate the effec t of
      coadministration of a protein pump inhibitor, an inhibitor of P-glycoprotei n and CYP3A4, or
      an inhibitor of CYP2C9 on the pharmacokinetics of vismodegib  i n healthy female subjects of
      non-childbearing potential. Subjects will be random ized to receive multiple oral doses of
      vismodegib, alone or in combination with multiple oral doses of either rabeprazole,
      itraconazole or fluconazole. Anticipa ted time on study treatment is up to 11 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Relative effect of rabeprazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)</measure>
    <time_frame>up to 12 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative effect of itraconazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)</measure>
    <time_frame>up to 12 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative effect of fluconazole on the steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)</measure>
    <time_frame>up to 12 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A: Vismodegib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Rabeprazole + Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Itraconazole + Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Fluconazole + Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vismodegib</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>A: Vismodegib</arm_group_label>
    <arm_group_label>B: Rabeprazole + Vismodegib</arm_group_label>
    <arm_group_label>C: Itraconazole + Vismodegib</arm_group_label>
    <arm_group_label>D: Fluconazole + Vismodegib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabeprazole</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>B: Rabeprazole + Vismodegib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>C: Itraconazole + Vismodegib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluconazole</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>D: Fluconazole + Vismodegib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females of non-childbearing potential

          -  Body mass index (BMI) 18 to 32 kg/m2, inclusive

          -  In good health, determined by no clinically significant findings from medical
             history, physical examination. 12-lead ECG, and vital signs

          -  Clinical laboratory evaluations, complete blood count and urinalysis within the
             normal range for the test laboratory, unless not deemed clinically significant by the
             investigator

          -  Negative test for drugs of abuse at screening and check-in (including alcohol)

          -  Negative for hepatitis B, hepatitis C and HIV infection

          -  Non-childbearing potential is defined as: non-pregnant, non-lactating, and either
             postmenopausal for at least 1 year or surgically sterile (e.g. bilateral oophorectomy
             and/or hysterectomy)

        Exclusion Criteria:

          -  Significant history or clinical evidence of any metabolic (including type 1 or 2
             diabetes). allergic, dermatological, hepatic, renal, hematological, pulmonary,
             cardiovascular, endocrine, GI (including gastric or duodenal ulcers),
             Zollinger-Ellison syndrome, Barrett's esophagus, urological, neurological, or
             psychiatric disorder

          -  History of inflammatory arthritis

          -  History of symptomatic hypotension

          -  History of seizure disorders

          -  History of bipolar or major depressive disorder

          -  History of stomach or intestinal surgery or resection that would potentially alter
             absorption and/or excretion of orally administered drugs (appendectomy, hernia
             repair, and/or cholecystectomy will be allowed)

          -  History of alcoholism or drug addiction within 1 year prior to check-in

          -  Use of any tobacco- or nicotine-containing products within 6 months prior to check-in

          -  Participation in any other investigational study drug or biological agent trial in
             which receipt of investigational study drug occurred within 5 half-lives or 30 days,
             whichever is longer, prior to check-in

          -  Use of PPIs, H2-receptor antagonists, or antacids within 1 month prior to check-in

          -  History of chronic PPI use (&gt; 30 days of continuous daily dosing) within 6 months of
             check-in
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>January 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
